Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1971 1
1972 1
1973 2
1974 2
1975 1
1977 2
1978 2
1979 6
1980 4
1981 3
1982 2
1983 3
1984 3
1985 2
1986 1
1987 4
1988 2
1989 2
1990 1
1991 9
1992 7
1993 3
1994 2
1995 4
1996 6
1997 6
1998 4
1999 2
2000 5
2001 2
2002 1
2003 2
2004 3
2005 5
2006 11
2007 6
2008 4
2009 3
2010 9
2011 5
2012 10
2013 6
2014 6
2015 12
2016 17
2017 20
2018 17
2019 18
2020 19
2021 15
2022 9
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Results by year

Filters applied: . Clear all
Page 1
Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Shah MH, et al. Among authors: brock p. J Natl Compr Canc Netw. 2021 Jul 28;19(7):839-868. doi: 10.6004/jnccn.2021.0032. J Natl Compr Canc Netw. 2021. PMID: 34340212
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
Freyer DR, Brock PR, Chang KW, Dupuis LL, Epelman S, Knight K, Mills D, Phillips R, Potter E, Risby D, Simpkin P, Sullivan M, Cabral S, Robinson PD, Sung L. Freyer DR, et al. Among authors: brock pr. Lancet Child Adolesc Health. 2020 Feb;4(2):141-150. doi: 10.1016/S2352-4642(19)30336-0. Epub 2019 Dec 19. Lancet Child Adolesc Health. 2020. PMID: 31866182 Free PMC article. Review.
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Brock PR, et al. N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109. N Engl J Med. 2018. PMID: 29924955 Free PMC article. Clinical Trial.
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Park JR, et al. Among authors: brock p. J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471719 Free PMC article. Review.
New insights into cisplatin ototoxicity.
Brock PR. Brock PR. Cancer. 2022 Jan 1;128(1):43-46. doi: 10.1002/cncr.33847. Epub 2021 Sep 7. Cancer. 2022. PMID: 34490622 Free article.
Multiple Endocrine Neoplasia Type 4.
Brock P, Kirschner L. Brock P, et al. 2023 Sep 21. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2023 Sep 21. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 37733893 Free Books & Documents. Review.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Among authors: brock p. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
Infantile fibrosarcoma.
Brock P, Renard M, Smet M, De Wever I, Van Daele MC. Brock P, et al. Med Pediatr Oncol. 1991;19(3):210. doi: 10.1002/mpo.2950190314. Med Pediatr Oncol. 1991. PMID: 2023570 No abstract available.
Ten challenges in the management of neuroblastoma.
Gains J, Mandeville H, Cork N, Brock P, Gaze M. Gains J, et al. Among authors: brock p. Future Oncol. 2012 Jul;8(7):839-58. doi: 10.2217/fon.12.70. Future Oncol. 2012. PMID: 22830404 Review.
278 results